Pan Jiang

Dr. Pan Jiang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Translational Oncology
Verified
Journal Article
Open access
PJPan Jiang
Pan Jiang
YLYanli Li
Yanli Li
ZXZheng Xu
Zheng Xu
SHShengteng He
Shengteng He
Head and neck squamous cell carcinoma (HNSCC) is an invasive malignancy with high worldwide mortality. Growing evidence has indicated a pivotal correlation between HNSCC prognosis and immune signature. This study investigated an immune-related gene pairs (IRGPs) signature to predict the prognostic value of HNSCC patients. We constructed IRGPs via integrating multiple IRG expression data sets. Moreover, we established the predictive model base on the IRGPs for HNSCC, and utilized multidimensional bioinformatics methods to validate the robustness of prognostic value of the IRGPs signature. In addition, we explored the relationship between the IRGPs model and immune status. Seventeen IRGPs signature was built as the predictive model which predicted prognosis independently and reliably for HNSCC. Compared to the high-risk group, the low-risk group demonstrated a distinctly favorable prognosis including overall survival (OS), disease-specific survival (DSS), and progression-free survival (PFS). The low-risk group showed higher-immune score and lower-tumor purity than the high-risk group. In addition, the low-risk group exhibited higher expression of Programmed cell death 1 ligand 1 (PD-L1) and Microsatellite instability (MSI) score, and lower expression of Tumor Immune Dysfunction and Exclusion (TIDE), which indicated the low-risk group was much more sensitive to immunotherapy. Lastly, the IRGs signature has achieved a higher accuracy than clinical properties for estimation of survival. The IRGPs model is an independent biomarker for estimating the prognosis, and could be also used to predict immunotherapeutic response in HNSCC patients. These findings may provide new ideas for novel biomarkers and may be helpful to formulate personalized immunotherapy strategy.

3 September 2024 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
FXFeng Xu
Feng Xu
HJHui Jiang
Hui Jiang
FLFanglan Li
Fanglan Li
YWYan Wen
Yan Wen
PJPan Jiang
Pan Jiang
YFYongwen Feng
Yongwen Feng
Background: As a novel indicator of inflammation, the relationship between the systemic immune-inflammation index (SIRI) and mortality in patients with asthma remains uncertain. Our study aimed to explore the association between SIRI and mortality in asthma patients.Methods: Data from the National Health and Nutrition Examination Survey (NHANES) for US adults from 2001 to 2018 were included in this study. Then, we divided all patients into three groups based on SIRI tertiles and used multivariable weighted Cox regression analysis, smoothing curve fitting, survival curve analysis, and subgroup analysis to investigate the relationship between SIRI and asthma.Results: A total of 6,156 participants were included in the study, with each SIRI tertile consisting of 2052 individuals. Asthma patients with higher SIRI levels were older, had a higher level of education, were more likely to be married, and had a higher chance of being smokers. In Cox proportional-hazards models, the highest SIRI group showed higher hazard ratios (HRs) for all-cause mortality in individuals with asthma after adjusting for potential confounders. The restricted cubic spline analysis indicated a non-linear relationship between SIRI and all-cause mortality. The Kaplan–Meier survival curves showed that patients with higher SIRI levels had a higher risk of all-cause mortality. Subgroup analyses revealed SIRI’s association with all-cause mortality across various demographics, including age, sex, race, education levels, smoking status, and marital status.Conclusion: Our study provides evidence for the relationship between SIRI and mortality in asthma patients. SIRI may potentially serve as a predictive tool for evaluating asthma mortality rates.

26 April 2025 in npj Primary Care Respiratory Medicine
Verified
Journal Article
Open access
PDF file
FXFeng Xu
Feng Xu
YFYongwen Feng
Yongwen Feng
JLJibo Li
Jibo Li
XLXinlong Liu
Xinlong Liu
HLHaoda Liang
Haoda Liang
PJPan Jiang
Pan Jiang
Chronic respiratory diseases (CRD) are major contributors to mortality. The “obesity paradox” suggests that higher body mass index (BMI) may confer survival benefits in CRD patients. This study investigates the association between BMI and mortality risk in CRD patients, focusing on the mediating role of the triglyceride-glucose (TyG) index. A cross-sectional analysis of 7689 participants with CRD was conducted. Participants were categorized by BMI into <25.0, 25.0–29.9, 30.0–34.9, 35.0–39.9, and ≥40 kg/m2. Outcomes included all-cause mortality, cardiovascular disease (CVD) mortality, and non-CVD mortality. Cox regression models assessed associations, and mediation analysis evaluated the role of the TyG index. Among 7689 CRD patients, higher BMI was associated with lower all-cause mortality (HR for BMI 25.0–29.9: 0.81, 95% CI 0.70–0.94; HR for BMI 30.0–34.9: 0.72, 95% CI 0.61–0.85; HR for BMI 35.0–39.9: 0.72, 95% CI 0.59–0.88; HR for BMI ≥ 40: 0.82, 95% CI 0.66–1.02) and non-CVD mortality (HR for BMI 25.0–29.9: 0.77, 95% CI 0.65–0.91; HR for BMI 30.0–34.9: 0.65, 95% CI 0.54–0.79; HR for BMI 35.0–39.9: 0.66, 95% CI 0.52–0.83; HR for BMI ≥ 40: 0.69, 95% CI 0.53–0.89), but not CVD mortality. The TyG index mediated a significant proportion of the association between BMI and mortality (mediation effects: −22.39 to −18.49%). Kaplan-Meier survival curves and restricted cubic spline regression further illustrated the significant associations between BMI and all-cause mortality and non-CVD mortality, while no significant association was observed for CVD mortality. Higher BMI is associated with lower mortality risk in CRD patients, particularly for non-CVD causes, mediated by the TyG index. This highlights the potential role of insulin resistance in the “obesity paradox” and suggests that metabolic health interventions may improve outcomes in CRD.

26 September 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
FXFeng Xu
Feng Xu
PJPan Jiang
Pan Jiang
Objective: This study aimed to evaluate the predictive roles of hematologic inflammatory biomarkers, including the neutrophil-percentage-to-albumin ratio (NPAR), neutrophil-to-lymphocyte ratio (NLR), and eosinophil-to-lymphocyte ratio (ELR), in relation to mortality among individuals with chronic respiratory diseases (CRDs).Methods: We analyzed data from the National Health and Nutrition Examination Survey (NHANES) to assess the relationship between these inflammatory biomarkers and mortality in adults with CRDs. Multivariable Cox regression models were used to estimate hazard ratios (HRs) for all-cause mortality, adjusting for potential confounders. Receiver operating characteristic (ROC) curve analysis was employed to evaluate the predictive performance of these biomarkers, with the area under the curve (AUC) used to compare their accuracy.Results: A total of 8,387 participants with CRDs were included in the analysis. Higher levels of NPAR were significantly associated with increased all-cause mortality (HR = 1.33, 95% CI: 1.26–1.40, P < 0.001). Similarly, elevated NLR was associated with higher mortality risk (HR = 1.24, 95% CI: 1.17–1.30, P < 0.001). In contrast, ELR did not show a significant association with mortality (HR = 1.04, 95% CI: 0.99–1.10, P = 0.098). ROC curve analysis revealed that NPAR had the highest AUC value (0.639, 95% CI: 0.623–0.656), suggesting modest yet relatively better discriminative capacity among the evaluated biomarkers for mortality risk stratification.Conclusion: Among individuals with chronic respiratory diseases, higher NPAR and NLR are significant predictors of mortality, with statistically significant but moderate predictive ability as indicated by their AUC values. These findings suggest that NPAR and NLR may serve as useful biomarkers for risk stratification in patients with CRDs, though their clinical utility is limited by modest predictive power.